A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of March 27, 2025
Completed
Keywords
ClinConnect Summary
Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.
HIV infected patients who are presumed to have neurosyphilis or have definitive neurosyphilis are treated for the neurosyphilis with either penicillin G or ceftriaxone. Patients are treated for 10 days and followed for 50 weeks after treatmen...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Concurrent Medication:
- Allowed:
- • Antiretroviral drugs.
- • Concurrent treatment for opportunistic infections with non-antisyphilitic drugs.
- • Metronidazole, aminoglycosides, trimethoprim / sulfamethoxazole (TMP / SMX), polymyxin, vancomycin, dapsone, pentamidine, acyclovir, antifungals, clindamycin, immunomodulators, and quinolones.
- Patients must:
- • Have HIV infection.
- • Have presumable or documented neurosyphilis.
- • Be capable of giving informed consent.
- • Have life expectancy of at least 52 weeks.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following conditions or symptoms are excluded:
- • History of penicillin or cephalosporin immediate hypersensitivity reaction characterized by angioneurotic edema, hyperemia, urticaria, bronchospasm, and/or anaphylaxis.
- • History of mucosal or blistering rash in response to related treatment.
- Concurrent Medication:
- Excluded:
- • Antitreponemal therapy (amoxicillin, doxycycline, tetracycline hydrochloride, erythromycin, procaine penicillin, any beta lactam, or chloramphenicol).
- Patients with the following are excluded:
- • Other etiology of cerebrospinal (CSF) abnormalities other than HIV and syphilis infection in patients who present with clinical symptoms (this is not required in asymptomatic patients).
- Prior Medication:
- Excluded:
- • Treatment for syphilis within 1 year prior to study entry.
- • Antitreponemal therapy (amoxicillin, doxycycline, tetracycline hydrochloride, erythromycin, procaine penicillin, any beta lactam, or chloramphenicol) within 45 days prior to study entry.
- • Unwilling or unable to comply with follow-up schedule, including repeat lumbar punctures.
Trial Officials
Hook EW III
Study Chair
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
San Francisco, California, United States
Indianapolis, Indiana, United States
Indianapolis, Indiana, United States
Springfield, Massachusetts, United States
Bronx, New York, United States
Bronx, New York, United States
Bronx, New York, United States
Bronx, New York, United States
Bronx, New York, United States
New York, New York, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Seattle, Washington, United States
San Diego, California, United States
New York, New York, United States
New York, New York, United States
Rochester, New York, United States
Chapel Hill, North Carolina, United States
Torrance, California, United States
New Haven, Connecticut, United States
Miami, Florida, United States
Baltimore, Maryland, United States
Bronx, New York, United States
Bronx, New York, United States
Bronx, New York, United States
Brooklyn, New York, United States
Buffalo, New York, United States
East Meadow, New York, United States
Syracuse, New York, United States
Cincinnati, Ohio, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Charleston, South Carolina, United States
Key West, Florida, United States
Miami, Florida, United States
Miami, Florida, United States
Boston, Massachusetts, United States
New Brunswick, New Jersey, United States
Chapel Hill, North Carolina, United States
Charlotte, North Carolina, United States
Seattle, Washington, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials